NASDAQ:LEGN Legend Biotech (LEGN) Stock Price, News & Analysis $17.03 -0.64 (-3.62%) As of 11:15 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Legend Biotech Stock (NASDAQ:LEGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Legend Biotech alerts:Sign Up Key Stats Today's Range$17.08▼$18.0450-Day Range$17.67▼$27.8752-Week Range$16.24▼$37.50Volume856,190 shsAverage Volume2.44 million shsMarket Capitalization$3.30 billionP/E RatioN/ADividend YieldN/APrice Target$53.14Consensus RatingHold Company Overview Legend Biotech Corporation (NASDAQ: LEGN) is a global biotechnology company focused on developing, manufacturing and commercializing novel cell therapies for the treatment of cancer and other serious diseases. The company’s work centers primarily on chimeric antigen receptor T-cell (CAR-T) therapies designed to harness a patient’s immune system to recognize and attack cancer cells. Legend Biotech’s lead product is CARVYKTI (ciltacabtagene autoleucel), a B-cell maturation antigen (BCMA)-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. CARVYKTI was developed through a strategic collaboration with Janssen Biotech, part of Johnson & Johnson, which supports the product’s global development and commercialization. Legend also maintains a pipeline of investigational cell therapies targeting additional hematologic malignancies and solid tumors. Founded in 2014, Legend Biotech has operations spanning the United States, China and other international markets, with activities covering research, clinical development, regulatory support and cell-therapy manufacturing. The company is headquartered in Somerset, New Jersey. Its leadership includes Ying Huang, Ph.D., who serves as chief executive officer and has guided the company’s expansion as it advances its cell-therapy platform and commercial operations.AI Generated. May Contain Errors. Read More Legend Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreLEGN MarketRank™: Legend Biotech scored higher than 70% of companies evaluated by MarketBeat, and ranked 222nd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingLegend Biotech has received a consensus rating of Hold. The company's average rating score is 2.47, and is based on no strong buy ratings, 8 buy ratings, 6 hold ratings, and 1 sell rating.Upside PotentialLegend Biotech has a consensus price target of $53.14, representing about 200.8% upside from its current price of $17.67.Amount of Analyst CoverageLegend Biotech has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Legend Biotech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Legend Biotech are expected to grow in the coming year, from ($0.05) to $1.17 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Legend Biotech is -70.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Legend Biotech is -70.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLegend Biotech has a P/B Ratio of 3.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Legend Biotech's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.50% of the float of Legend Biotech has been sold short.Short Interest Ratio / Days to CoverLegend Biotech has a short interest ratio ("days to cover") of 9.03.Change versus previous monthShort interest in Legend Biotech has recently decreased by 7.57%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLegend Biotech does not currently pay a dividend.Dividend GrowthLegend Biotech does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.71 News SentimentLegend Biotech has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Legend Biotech this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for LEGN on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat Follows6 people have added Legend Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Legend Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $82,265.00 in company stock.Percentage Held by Insiders0.02% of the stock of Legend Biotech is held by insiders.Percentage Held by Institutions70.89% of the stock of Legend Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Legend Biotech's insider trading history. Receive LEGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LEGN Stock News HeadlinesLEGN’s new CEO from Novartis paves way for buyout speculationSeptember 15 at 11:34 PM | msn.comLegend Biotech Appoints Ingrid Zhang as CEOSeptember 15 at 1:33 PM | finance.yahoo.comNNVC on Alert: FDA Validation and Outperform Rating!NanoViricides (NYSE: NNVC) just landed FDA Rare Pediatric Disease Designation for NV-387 in Measles, adding to its existing Orphan Drug Designation and opening a path toward a Priority Review Voucher, assets that have recently sold for around 195 million dollars. Noble Capital Markets initiated coverage with an Outperform rating and a 6 dollar price target, citing NNVC's broad-spectrum nanoviricide technology and its potential across Measles, MPox, Smallpox, and Ebola, where a Phase II trial is advancing in the Democratic Republic of Congo.September 16 at 1:00 AM | Equiscreen (Ad)Legend Biotech taps Novartis veteran Zhang as CEOSeptember 15 at 8:46 AM | reuters.comLegend Biotech Appoints Ingrid Zhang as Chief Executive OfficerSeptember 15 at 8:00 AM | globenewswire.comLegend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in JulySeptember 15 at 7:30 AM | wsj.comBarclays Sticks to Its Buy Rating for Legend Biotech (LEGN)September 12, 2026 | theglobeandmail.comRBC Capital Sticks to Its Buy Rating for Legend Biotech (LEGN)September 12, 2026 | theglobeandmail.comSee More Headlines LEGN Stock Analysis - Frequently Asked Questions How have LEGN shares performed this year? Legend Biotech's stock was trading at $21.74 at the beginning of the year. Since then, LEGN shares have decreased by 18.7% and is now trading at $17.67. How were Legend Biotech's earnings last quarter? Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) issued its earnings results on Tuesday, August, 11th. The company reported $0.09 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.07 by $0.02. The business's revenue for the quarter was up 51.9% compared to the same quarter last year. Read the conference call transcript. When did Legend Biotech IPO? Legend Biotech (LEGN) raised $350 million in an IPO on Friday, June 5th 2020. The company issued 18,425,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies acted as the underwriters for the IPO. Who are Legend Biotech's major shareholders? Legend Biotech's top institutional shareholders include Montanova Capital LLC (3.81%), Assenagon Asset Management S.A. (1.03%), Squarepoint Ops LLC (0.40%) and Tidal Investments LLC (0.12%). View institutional ownership trends. How do I buy shares of Legend Biotech? Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Legend Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Legend Biotech investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Meta Platforms (META), Arista Networks (ANET), Jabil (JBL) and e.l.f. Beauty (ELF). Company Calendar Last Earnings8/11/2026Today9/16/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 LEGN's financial health is in the Red zone, according to TradeSmith. LEGN has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LEGN CIK1801198 Webwww.legendbiotech.com Phone732-317-5050FaxN/AEmployees2,965Year Founded2014Price Target and Rating Average Price Target for Legend Biotech$53.14 High Price Target$74.00 Low Price Target$24.00 Potential Upside/Downside+203.7%Consensus RatingHold Rating Score (0-4)2.47 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($0.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$296.80 million Net Margins-7.21% Pretax Margin-4.42% Return on Equity-8.71% Return on Assets-5.40% Debt Debt-to-Equity RatioN/A Current Ratio3.04 Quick Ratio2.94 Sales & Book Value Annual Sales$1.03 billion Price / Sales3.30 Cash FlowN/A Price / Cash FlowN/A Book Value$5.43 per share Price / Book3.22Miscellaneous Outstanding Shares193,770,000Free Float193,730,000Market Cap$3.39 billion OptionableOptionable Beta0.40 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:LEGN) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our Partners“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...Brownstone Research | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredNNVC on Alert: FDA Validation and Outperform Rating!NanoViricides (NYSE: NNVC) just landed FDA Rare Pediatric Disease Designation for NV-387 in Measles, adding to...Equiscreen | SponsoredYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...Porter & Company | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Legend Biotech Corporation Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Legend Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
